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Abstract
A recent genome wide association study (GWAS) demonstrated that more than 100 genetic variants influence the risk of
multiple sclerosis (MS). We investigated what proportion of the general population can be considered at high genetic risk of
MS, whether genetic information can be used to predict disease development and how the recently found genetic
associations have influenced these estimates. We used summary statistics from GWAS in MS to estimate the distribution of
risk within a large simulated general population. We profiled MS associated loci in 70 MS patients and 79 healthy controls
(HC) and assessed their position within the distribution of risk in the simulated population. The predictive performance of a
weighted genetic risk score (wGRS) on disease status was investigated using receiver operating characteristic statistics.
When all known variants were considered, 40.8% of the general population was predicted to be at reduced risk, 49% at
average, 6.9% at elevated and 3.3% at high risk of MS. Fifty percent of MS patients were at either reduced or average risk of
disease. However, they showed a significantly higher wGRS than HC (median 13.47 vs 12.46, p= 4.08610210). The predictive
performance of the model including all currently known MS associations (area under the curve = 79.7%, 95%CI = 72.4%–
87.0%) was higher than that of models considering previously known associations. Despite this, considering the relatively
low prevalence of MS, the positive predictive value was below 1%. The increasing number of known associated genetic
variants is improving our ability to predict the development of MS. This is still unlikely to be clinically useful but a more
complete understanding of the complexity underlying MS aetiology and the inclusion of environmental risk factors will aid
future attempts of disease prediction.
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Introduction
Multiple sclerosis (MS) is a complex disorder of the central
nervous system with a strong genetic component [1]. Indeed, the
risk of developing this condition in biological relatives of MS
patients increases with increasing degree of kinship; this observa-
tion has provided the rationale for genetic studies in MS [2].
The main genetic locus for MS (the HLA-DRB1*1501 allele) was
discovered in the 1970s within the major histocompatibility
complex (MHC) region, long before the era of genome wide
association studies (GWAS) [3]. However, the genetic role in MS
susceptibility is not limited to the MHC, and the development of
GWAS has provided further insights into MS genetics. Two
studies published in 2011 by the International Multiple Sclerosis
Genetics Consortium (IMSGC) and the Wellcome Trust Case
Control Consortium 2 provided evidence for approximately 60
single nucleotide polymorphisms (SNPs) located outside the MHC
influencing MS risk [4,5]. More recently, the IMSGC performed
an updated GWAS that included almost 30,000 MS patients and
used a novel SNP array (the ImmunoChip, (Illumina INC, USA))
specifically designed for immune mediated diseases such as MS.
This study was able to further increase the number of known MS
associated variants to 110 [6].
The identification of individuals carrying a considerably high
genetic risk of MS in the general population could be relevant for
the development of disease prevention strategies and holds major
public health implications. However, it remains unclear what
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proportion of the general population can be considered at
substantially increased risk of disease and whether we will ever
be able to predict MS development based on genetic information
alone. Previous attempts to do so using GWAS data have shown
that genetics is only moderately able to discriminate between MS
patients and healthy individuals and that this is still far from being
useful clinically [7–9]. We aimed to investigate whether the
predictive performance of MS genetic associations has changed
given that their number has now exceeded the remarkable
threshold of 100.
Methods
We extracted summary statistics (odds ratios (OR) and risk allele
frequencies) for all currently known MS associations located
outside the MHC from the recent ImmunoChip based GWAS
performed by the IMSGC [6]. This article did not report
association results within the MHC and therefore summary
statistics regarding the HLA-DRB1 association were extracted from
a previous meta-analysis also published by the IMSGC in 2011
[5].
The R package ‘‘REGENT’’ (Risk Estimation for Genetic and
Environmental Traits) was used to estimate the proportion of
population predicted to be at reduced, average, elevated and high
risk of MS under three separate models considering: 1) only the
HLA-DRB1 association; 2) HLA-DRB1 + associations known in
2011 (Old SNPs) (n = 62) [4,5]; 3) HLA-DRB1 + all currently
known associations (full model, n = 110) (Table S1) [6]. REGENT
applies summary GWAS statistics to a large simulated population.
In particular, the distribution of genotypes across 100,000
hypothetical individuals is simulated based on the allelic frequen-
cies reported in published GWAS assuming the presence of
Hardy-Weinberg Equilibrium. Secondly, the odds ratios reported
for each SNP and the sample size used in the original association
study are used to calculate the overall risk of each individual
profile with 95% confidence intervals (CI) assuming a multiplica-
tive model between alleles. These estimates of risk are scaled by
the risk profile which is closest to the mean risk of the simulated
population (baseline risk) to calculate an individual relative risk
(RR) [10,11]. All individuals with 95%CI overlapping with the
95%CI of the baseline risk profile are defined at average risk (i.e.
their risk is not significantly different from the baseline risk). The
remaining individuals are also grouped into additional risk
categories (reduced, elevated and high) based on their 95%CI
(i.e. individuals at reduced and elevated risk of disease are those
whose 95%CI lie below and above the baseline profile 95%CI
respectively; individuals at high risk are those whose 95%CI lie
above the 95%CI of the first elevated risk profile) [10,11].
Blood was drawn, DNA extracted and MS associated variants
profiled using the ImmunoChip (Illumina INC, USA) in a total of
73 MS patients and 99 ethnically matched healthy controls (HC)
recruited at the Blizard Institute, Queen Mary University (White-
chapel, London, United Kingdom). Allele frequencies, missing
genotypes and Hardy-Weinberg equilibrium tests for each
investigated SNP are reported in Table S2. After excluding those
samples with more than 10% missing genotypes, 70 MS and 79
HC were used for analysis. We used REGENT to estimate how
many MS and HC were included in each category of risk under
each model [10]. Furthermore, a weighted genetic risk score
(wGRS) was calculated for each individual as described in De
Jager et al (i.e. by multiplying the number of risk alleles by the
weight of each SNP and then taking the sum across all associations
considered) [7]. The ability of this estimate of risk to predict MS
status was assessed using receiver operating characteristic (ROC)
curve. Differences in the predictive performance of different
genetic models were tested using the DeLong’s test for correlated
ROC curves in the R package ‘‘pROC’’. This study was
conducted according to the principles expressed in the Declaration
of Helsinki and obtained ethical permission (East London REC 1
(ref. 10/H0704/62)). All participants provided their written
consent to participate in this study using a standardised consent
form approved by the ethics committee. Individual genotypes of
MS patients and HC are available on request.
Results
The distribution of risk across the simulated general population
considerably varied based on the genetic variants that were
considered in the analysis. For example, when only the HLA-DRB1
association was considered, all individuals were grouped in three
risk categories (average, elevated and high) corresponding to their
HLA-DRB1 status (homozygous DRB1*15 negative, DRB1*15
heterozygous and homozygous DRB1*15 positive) (figure 1,
table 1). This is because only these three genotypes are possible
at this locus and based on the allelic frequency of the MS
associated HLA-DRB1 allele, the baseline risk used as reference to
calculate risk categories is the one of homozygous negative
individuals.
When old associated SNPs were included in the model, the RR
of MS appeared more continuously distributed across the
population and the proportion of individuals at reduced, average,
elevated and high risk was 44.8%, 41.6%, 7.5% and 6.1%
respectively (figure 1, table 1). Including the more recent
associations did not substantially change these estimates and a
substantial proportion of population (40.8%) was still predicted to
be at reduced (RR 95%CIs = 0.00–0.70), 49% at average (RR
95%CIs = 0.70–1.47), 6.9% at elevated (RR 95%CIs = 1.47–2.71)
and 3.3% at high risk of MS (RR 95%CIs = 2.71–Inf) (figure 1 and
table 1).
We then estimated the proportion of our genotyped MS and
HC individuals within the risk categories defined by REGENT
under each genetic model. We found that the proportion of MS
patients identified at elevated and high risk of disease was
consistently higher than that of HC. When the full model was
considered, 20% and 30% of MS patients vs 15.2% and 8.9% of
HC were at elevated and high risk of MS respectively (table 2).
However, even when all known variants were included in the
model, 50% of MS patients were at either average or reduced risk
of disease.
We then calculated the wGRS of each MS and HC individual
and compared the distribution of this variable between the two
groups. In each model, MS patients had a higher wGRS than HC
(figure 2 and table 2). The median wGRS of MS vs HC were 1.09
vs 0.00 (when considering only HLA-DRB1), 9.14 vs 8.15 (when
considering HLA-DRB1 + old SNPs) and 13.47 vs 12.46 (when
considering HLA-DRB1 + all known SNPs). The difference in
wGRS between MS and HC was statistically significant in all
considered models (table 2). We next assessed the predictive
performance of each model using ROC curves and tested whether
this has been considerably influenced by the discovery of
additional MS genetic associations. The HLA-DRB1 was on its
own moderately able to discriminate between MS patients and
HC (area under the curve (AUC) = 70.8% (95%CI= 63.4%–
78.2%)). The AUC progressively increased to 76.6%
(95%CI=69.1%–84.2%) and to 79.7% (95%CI= 72.4%–87.0%)
when including old SNPs and all currently known SNPs in the
model respectively (figure 3). In the full model, the best wGRS
threshold (i.e. the one providing the best sum of sensitivity +
Genetic Prediction of MS
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e96578
specificity) was 13.0 and this corresponded to a sensitivity of 71.4%
and a specificity of 78.5% (figure 3). The AUC of models
excluding HLA-DRB1 and considering either old or all SNPs were
66.0% (95%CI= 57.2%–74.8%) and 69.3% (95%CI= 60.9%–
77.8%) respectively.
The difference between predictive performances was significant
between the model considering only HLA-DRB1 vs the one
considering HLA-DRB1 + all SNPs (p=0.016), while HLA-DRB1
vs HLA-DRB1 + old SNPs and HLA-DRB1 + old SNPs vs HLA-
DRB1 + all SNPs trended towards significance (p=0.054 and
p=0.13 respectively). However, when the prevalence of MS in the
general population was considered (approximately 1/1,000), the
positive predictive value of the full model was below 1% (i.e. the
probability of having MS given a wGRS.13.0) [12].
Discussion
Our knowledge of the genetics of complex diseases has greatly
advanced in the last few years and the development of genome-
wide analyses has enabled the discovery of more than 100
common variants influencing the risk of MS located outside the
MHC. It seems plausible that even more variants could be
discovered by further increasing the sample size and the
statistical power of GWAS. MS researchers should therefore
ponder upon what we have learnt from genetic studies in MS
and what can potentially be derived from future ones. GWAS
data have been extremely useful in helping us to improve our
understanding of MS aetiology and its immunological nature.
For example, gene-ontology analyses interrogating the genes
located within MS-associated genomic regions have shown a
Figure 1. GWAS statistics (OR and risk allele frequencies) were used to simulate a population of 100,000 individuals under different
models considering: only HLA-DRB1, HLA-DRB1 + MS associations known in 2011 and HLA-DRB1 + all currently known MS
associations. Categories of risk were defined based on the 95%CI of risk of each individual (see methods). Green= reduced risk, blue = average risk,
yellow= elevated risk, red = high risk.
doi:10.1371/journal.pone.0096578.g001
Genetic Prediction of MS
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e96578
Figure 2. Boxplots of weighted genetic risk score (wGRS) in MS patients and HC considering only HLA-DRB1, HLA-DRB1 + MS
associations known in 2011 and HLA-DRB1 + all currently known MS associations. The wGRS was calculated by multiplying the number of
risk alleles by the weight of each SNP and then taking the sum across all associations (see methods). The whiskers extend to the most extreme data point
which is no more than 1.5 times the IQR from the box.
doi:10.1371/journal.pone.0096578.g002
Table 1. Proportion of population and 95%CIs for each category of risk considering only HLA-DRB1, HLA-DRB1 + MS associations
known in 2011 and HLA-DRB1 + all currently known MS associations.
Model considered Risk Category
Reduced Average Elevated High
HLA-DRB1 95% CI 0–0.89 0.89–1.12 1.12–3.27 3.27–Inf
Proportion of population 0.0% 63.8% 32.1% 4.1%
HLA-DRB1 + Old associations 95% CI 0–0.76 0.76–1.34 1.34–2.06 2.06–Inf
Proportion of population 44.8% 41.6% 7.5% 6.1%
HLA-DRB1 + All associations 95% CI 0–0.70 0.70–1.47 1.47–2.71 2.71–Inf
Proportion of population 40.8% 49.0% 6.9% 3.3%
In brief, GWAS statistics (OR and risk allele frequencies) are used to simulate a population of 100,000 individuals. An overall genetic risk of MS is calculated for each
individual and scaled by the mean risk profile. Categories of risk are defined based on the 95%CI of risk of each individual (see methods).
doi:10.1371/journal.pone.0096578.t001
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substantial overrepresentation of Immune-related processes
[4,13]. Similarly, the integration of GWAS and open chromatin
data has demonstrated that MS associated variants are
particularly active in CD4+ T helper, CD8+ cytotoxic T and
B cells [14]. What remains unclear today is whether genetic data
can be similarly useful in disease prediction.
We used summary genetic association statistics to estimate what
proportion of the general population can be predicted to be at a
significantly different risk of MS as compared to an average
baseline profile. We found that these estimates are clearly
influenced by the strength and the number of genetic variants
included in the model. As expected, considering one single variant
of strong effect (such as HLA-DRB1) identified three significantly
different risk categories in the population that correspond to the
three possible genotypes at this locus. The distribution of risk
became more continuous across the population when a larger
number of variants were included such as non-MHC SNPs known
in 2011 before the ImmunoChip study and novel ImmunoChip
Figure 3. Predictive performance of the wGRS assessed using receiver operating characteristic (ROC) curves when considering only
HLA-DRB1, HLA-DRB1 + MS associations known in 2011 and HLA-DRB1 + all currently known MS associations. The wGRS threshold
providing the best predictive performance is also shown (specificity and sensitivity within brackets).
doi:10.1371/journal.pone.0096578.g003
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associations. Notably, the full model indicated that most individ-
uals in the general population (about 90%) are either at average or
reduced risk of MS, 10% have a risk higher than average and an
extremely small fraction demonstrates a substantially increased
risk (e.g. more than 10 times the average risk). This is comparable
with previous estimates [15].
We then assessed to what extent two independent groups of MS
patients and HC differed in terms of their position within this risk
distribution. We found that in all considered genetic models, more
MS patients than HC were identified at either elevated or high risk
of disease. However, the inclusion of non-MHC SNPs in the
models did not increase the number of MS patients considered at
risk higher than average and, even when all variants were
considered, half of MS patients appeared at either average or
reduced risk of disease.
When the wGRS of MS was used as a predictor of disease status
using ROC, the predictive performance improved with the
increasing number of discovered associations and the best wGRS
threshold in the full model was associated with 71.4% sensitivity
and 78.5% specificity. This was significantly different from the
AUC obtained considering only the HLA-DRB1 association and
higher than that based on the variants known in 2011. The lack of
significance in the comparison between the models considering
HLA-DRB1 + all associations and HLA-DRB1 + old associations
should be interpreted with caution given the relatively small
sample size of this study and the p value trending towards
significance (p=0.13). Nevertheless, when the low prevalence of
MS was taken into account, the positive predictive value was very
low.
The main limitation of this study is represented by the small
sample size of MS patients and controls that were genotyped.
Although predictive performance estimates may be influenced by
increasing the sample size, our results are overall comparable with
those of previous studies [7–9]. For example, Isobe et al found that
MS patients from multi-case families have a greater genetic risk
score than sporadic cases, but the predictive power of this estimate
of genetic risk was still very limited [9]. Taken together, these
findings indicate that the bias towards a greater genetic score
found in MS patients is consistent across different sets of genetic
associations and can be found in a relatively small sample size of
patients and controls such as the one used in this study.
Furthermore, the recent discovery of additional MS associated
genetic variants has improved our ability to discriminate between
MS patients and healthy individuals. Despite this, genetic data are
still unlikely to be useful on their own and in this form for disease
prediction in clinical settings.
A number of factors need to be considered for MS prediction.
Several studies have implicated environmental agents in the
aetiology of this disease and in particular a history of Epstein Barr
virus infection, vitamin D deficiency and smoking [16]. Including
these variables in the model may increase the predictive
performance of the estimated risk. However, currently available
data suggest that risk estimates are unlikely to be massively
changed by considering the putative environmental agents in MS
[15].
If neither genetics nor environment can fully predict disease
development, then what determines MS onset? It is plausible that
the effect of a risk factor on disease development is influenced by
the presence or absence of additional agents. There is strong
evidence for such mechanisms in classical monogenic conditions
where the effect of mutations can be modified by epistatic
interactions with other genetic variants and environmental factors
[17,18]. For example, the effect of phenylalanine hydroxylase
mutations on the phenotype of phenylketonuria depends on
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dietary phenylalanine consumption [19]. Similarly, genetic vari-
ation on chromosome 21 has been reported to influence congenital
heart defects in Down’s syndrome patients (all of whom have
trisomy 21) [20]. It seems highly likely that similar mechanisms are
at play in more complex diseases such as MS. Furthermore,
environmental exposures both vary over time and are likely to act
at specific time points; and it is often difficult (if not impossible) to
take into account these factors in epidemiological studies [21,22].
Environmental associations are therefore more difficult to measure
with accuracy and this likely influences their potential role in
disease prediction. A more full understanding of the complexity of
MS, together with the interactions between risk factors and of the
time specificity of environmental agents is needed to aid future
attempts of disease prediction.
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